These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 12216092)

  • 1. Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma.
    Rao J; Seligson D; Visapaa H; Horvath S; Eeva M; Michel K; Pantuck A; Belldegrun A; Palotie A
    Cancer; 2002 Sep; 95(6):1247-57. PubMed ID: 12216092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma.
    Fromont G; Rouprêt M; Amira N; Sibony M; Vallancien G; Validire P; Cussenot O
    Eur Urol; 2005 Nov; 48(5):764-70. PubMed ID: 16126329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
    Mahnken A; Kausch I; Feller AC; Krüger S
    Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression.
    Mhawech P; Greloz V; Oppikofer C; Szalay-Quinodoz I; Herrmann F
    Cancer; 2004 Jun; 100(11):2367-75. PubMed ID: 15160340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
    Shariat SF; Kim JH; Ayala GE; Kho K; Wheeler TM; Lerner SP
    J Urol; 2003 Mar; 169(3):938-42. PubMed ID: 12576817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma.
    Krüger S; Mahnken A; Kausch I; Feller AC
    Eur Urol; 2005 Apr; 47(4):463-7. PubMed ID: 15774242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
    Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
    Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal immunoreactivity of the E-cadherin/catenin (alpha-, beta-, and gamma-) complex in premalignant and malignant non-melanocytic skin tumours.
    Papadavid E; Pignatelli M; Zakynthinos S; Krausz T; Chu AC
    J Pathol; 2002 Feb; 196(2):154-62. PubMed ID: 11793366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder.
    Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    Urol Oncol; 2007; 25(6):468-75. PubMed ID: 18047954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.
    Shi B; Laudon V; Yu S; Dong D; Zhu Y; Xu Z
    Urol Int; 2008; 81(3):320-4. PubMed ID: 18931551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
    Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ
    Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors.
    Bringuier PP; Umbas R; Schaafsma HE; Karthaus HF; Debruyne FM; Schalken JA
    Cancer Res; 1993 Jul; 53(14):3241-5. PubMed ID: 8324734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
    Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C
    Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the human mismatch repair gene hMSH2: a potential marker for urothelial malignancy.
    Leach FS; Hsieh JT; Molberg K; Saboorian MH; McConnell JD; Sagalowsky AI
    Cancer; 2000 May; 88(10):2333-41. PubMed ID: 10820356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors.
    Lascombe I; Clairotte A; Fauconnet S; Bernardini S; Wallerand H; Kantelip B; Bittard H
    Clin Cancer Res; 2006 May; 12(9):2780-7. PubMed ID: 16675571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up.
    Yin H; Leong AS
    Am J Clin Pathol; 2004 May; 121(5):679-87. PubMed ID: 15151208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multivariate analysis of recurrence in T1 bladder transitional cell carcinoma].
    Zhang J; Zeng L; Li GZ; Yang XY; Xia TL; Na YQ; Guo YL
    Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):475-7. PubMed ID: 14575574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
    Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
    Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.